Amyloidosis is a disorder of protein folding in which normally soluble plasma proteins aggregate in an abnormal fibrillar form causing progressive disruption to tissue structure and organ function. This review covers systemic AA and AL amyloidosis which may arise as a consequence of chronic respiratory conditions; the manifestations of both systemic and of localised amyloid deposition within the respiratory tract and provides a summary of current approaches to diagnosis and management. Amyloidosis and the lung HJ Lachmann and PN Hawkins 204 Chronic Respiratory Disease Amyloidosis and the lung HJ Lachmann and PN Hawkins 206 Chronic Respiratory Disease
Introduction
Amyloidosis describes a heterogeneous group of diseases in which normally soluble plasma proteins are deposited in the extracellular space in an abnormal insoluble fibrillar form. It may be either acquired or inherited and about 20 different proteins can form amyloid fibrils in vivo (Table 1) . 1 The ultrastructural morphology and histochemical properties of all amyloid fibrils, regardless of the precursor protein type, are remarkably similar [2] [3] [4] and diffraction studies of amyloid fibrils have confirmed that they all share a common core structure consisting of anti-parallel ␤-strands lying perpendicular to the long axis of the fibril. 5, 6 This extremely abnormal highly ordered conformation underlies the distinctive physicochemical properties of amyloid fibrils including their relative stability and resistance to proteolysis, and their ability to bind molecules of the dye Congo red in a spatially organized manner which results in the pathognomonic apple green birefringence when viewed under cross-polarised light. Amyloid deposits also always contain the normal plasma glycoprotein, serum amyloid P component (SAP) as a non-fibrillar constituent. The universal presence of SAP in amyloid deposits 7 reflects its specific binding to an, as yet, uncharacterized ligand common to all amyloid fibrils and this is the basis for diagnostic scintigraphic imaging of amyloid with radiolabelled SAP. 8 Amyloid deposition is remarkably diverse and can be localised or systemic, rapidly lethal or merely an incidental finding. 9 Clinically important amyloid deposits accumulate in the extracellular space, progressively disrupting the structure, integrity and function of affected tissues and organs. The natural history of amyloidosis is usually of progressive accumulation, but amyloid deposition is not irreversible and clinical progression of the amyloid diseases merely reflects that the fibrillar deposits are usually being laid down more rapidly than they are turning over. 10 Many of the conditions that underlie systemic amyloidosis are typically progressive and unremitting, but there are numerous reports describing regression of amyloid when associated inflammatory and other diseases have been successfully treated. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] 
Diagnosis and evaluation of amyloidosis
Histological confirmation of amyloid through Congo red staining producing red-green birefringence under cross-polarised light remains the diagnostic goldstandard ( Figure 1 ). 2 Most tissue specimens, ranging from needle biopsies to open surgical resections, can be studied although small biopsies are open to sampling error. Biopsy can be hazardous as there is an increased risk of haemorrhage, significant bleeds having been reported in 5% of liver biopsies 21 and the possibility should be considered when endobronchial and transbronchial biopsies are performed. This is due to the increased fragility of involved blood vessels, reduced elasticity of amyloidotic tissues, and, very occasionally in AL type, to an acquired deficiency of clotting factors IX or X. [22] [23] [24] [25] A less invasive alternative in suspected disease is fine needle aspiration and this has been used successfully in the respiratory tract. 26, 27 Positive histology for amyloid must be followed up by immunohistochemistry to determine the fibril protein type. 28 Suitable antibodies are widely available but, although immunohistochemistry usually yields definitive results in AA amyloidosis, it is frequently not diagnostic with AL deposits. 29, 30 Expertise in the immunohistochemical typing of hereditary amyloid is restricted, and definitive immunohistochemical typing of amyloid deposits cannot always be achieved. 31 Anatomical and functional evaluation of the tissues/ organs affected by amyloid need to be individually tailored, and in respiratory tract amyloidosis may include plain radiography, CT scanning, bronchoscopy and comprehensive respiratory function tests. Evidence of systemic disease should be sought clinically and by performing haematological and biochemical profiles ( Figure 2 ). The plasma cells clones that underlie systemic AL amyloidosis are often subtle and may not be detected by bone marrow examination or immunofixation of serum and urine; use of the new serum free light chain assays increases diagnostic sensitivity. 32 Immunoglobulin gene rearrangement studies may identify subtle clones in either the bone marrow or, in the case of localised AL, within the amyloidotic tissue itself. 33 Radiolabelled SAP localizes specifically to amyloid deposits in vivo in proportion to the quantity of amyloid present and thereby enables diagnosis, quantification and monitoring of amyloid. 8 Cardiac amyloidosis is best evaluated by a combination of echocardiography and ECG. [34] [35] [36] Two-dimensional Doppler echocardiography classically reveals concentric biventricular wall thickening with a restrictive filling pattern. 37 Amyloid causes diastolic dysfunction with well preserved contractility until a very late stage. 35 The ECG may be normal in patients with substantial cardiac amyloidosis, but in advanced disease commonly shows small voltages, pathological 'Q' waves (pseudo-infarct pattern) in the anterior chest leads and conduction abnormalities. The key to effective monitoring of amyloidosis and its treatment is relatively frequent repetition of these investigations bearing in mind that organ dysfunction may not closely reflect amyloid load.
Amyloidosis can present to respiratory physicians in a number of ways: first, chronic pulmonary conditions can themselves give rise to systemic amyloidosis; second, patients with systemic amyloidosis may present with respiratory symptoms; and third, localized pulmonary and respiratory tact amyloid deposits may either present with symptoms or be detected incidentally on chest radiography or biopsy and so on.
Systemic amyloidosis complicating respiratory diseases

Reactive systemic, AA, amyloidosis
Reactive systemic, AA, amyloidosis is a potential complication of any disorder associated with a sustained acute phase response and the list of chronic inflammatory, infective or neoplastic disorders that can underlie it is almost without limit ( Table 2) . Some of these conditions present to and are managed predominantly by respiratory physicians and others require pulmonary expertise within a multidisciplinary context. Biopsy and post-mortem series suggest that the prevalence of AA amyloid deposition in patients with chronic inflammatory diseases is between 3.6 and 5.8%, though a smaller proportion of patients have clinically significant amyloidosis. [38] [39] [40] The amyloid fibrils are derived from cleavage fragments of the circulating acute phase reactant, SAA (serum amyloid A protein). 41 SAA is an apolipoprotein of high density lipoprotein (HDL), 42 which, like C-reactive protein (CRP) is synthesized by hepatocytes under the transcriptional regulation of cytokines including IL-1, IL-6 and TNF-␣. 43 In health the circulating concentration of SAA is around 1 mg/L, but this can rise by more than a thousand-fold in the presence of inflammation. The circulating concentration of SAA tends to parallel that of the much more frequently measured CRP. A sustained high plasma level of SAA is a prerequisite for the development of AA amyloidosis but why amyloidosis develops in only a small proportion of cases remains unclear. The major respiratory diseases underlying AA amyloidosis in this country are bronchiectasis, the fifth commonest cause, accounting for 5% of cases in the UK, and lung neoplasia including Castlemans tumours, lymphoma and adenocarcinoma accounting for 3% of cases. Castleman's disease 44 or angiofollicular lymph node hyperplasia, is a rare B cell lymphoproliferative disorder characterized by giant hyperplastic lymph node follicles, capillary proliferation and plasma cell infiltration, and it is often associated with marked constitutional symptoms. It comprises solitary and multicentric forms, and there are hyaline vascular and plasma cell variants histologically. 45 Multicentric disease, commonly of the plasma cell type, often follows an aggressive and rapidly fatal course. Unicentric disease tends to occur in younger patients and is of the hyaline vascular type in more than 70% of cases, and of plasma cell type or mixed histology in the remainder. 46, 47 Most solitary tumours occur within the mediastinum and consist of a dominant mass surrounded by multiple enlarged lymph nodes which, histologically, may appear merely reactive. Constitutional symptoms including night sweats, fever and weight loss are common and laboratory abnormalities including anaemia, elevation of the erythrocyte sedimentation rate (ESR) and polyclonal hypergammaglobulinaemia are almost universal. Acquired systemic amyloidosis is a recognized rare complication of all forms of angiofollicular lymph node hyperplasia, and is usually of reactive systemic, AA, type occurring as a result of the persistent acute phase response. Surgical resection of unicentric tumours can result in complete remission and excellent long term outcome. 48 Other purely respiratory causes of AA amyloidosis are now fairly rare in the UK although in the first half of the last century tuberculosis was the commonest single disease resulting in AA amyloid and this remains the case in many parts of the developing world. Other less common associations include cystic fibrosis, sarcoidosis and Kartagener's syndrome. AA amyloidosis can present anytime between childhood and old age with a median age at presentation of 48 years in the UK. It is slightly commoner in men and, although disease can develop very rapidly, the median latency between presentation with a chronic inflammatory disorder and clinically significant amyloidosis is almost two decades.
AA amyloidosis usually presents with proteinuria followed by progressive renal dysfunction often accompanied by nephrotic syndrome. Splenic amyloid deposits are almost universally present ( Figure 3 ) but usually entirely asymptomatic, and amyloidotic spleens are frequently not palpable. Hepatic involvement and autonomic neuropathy are well recognized but usually occur very late in the disease. Cardiac amyloidosis occurs in less than 2% of cases. Respiratory tract involvement has not been a clinical feature among over 350 patients with systemic AA amyloidosis evaluated in our own unit and although there have been a few reports of systemic AA amyloidosis affecting the lungs, fibril typing was generally imperfect, 49 and all studies in which the fibril protein has actually been sequenced identified AL type. Diagnosis of amyloid relies on a high index of clinical suspicion and often requires histological confirmation. 50 SAP scintigraphy provides a useful non-invasive method of diagnosis in the UK National Amyloidosis Centre and can be used as a screening examination with greater than 98% accuracy in this type of amyloid. The most effective form of basic screening in medical or respiratory practice is to target those patients with ongoing poorly controlled inflammation and to perform urinalysis on each clinic attendance. More than 95% of patients with AA amyloidosis will have significant proteinuria on dipstick testing which should prompt further specialist investigation. The prognosis of AA amyloidosis depends on the degree of renal dysfunction at presentation and whether the underlying chronic inflammatory disease can be effectively suppressed, so that the plasma SAA is maintained below 10 mg/L. Treatment depends on the underlying diagnosis and may include surgery for cytokine secreting tumours or localized bronchiectasis, long term antimicrobials and postural drainage for chronic infections associated with structural lung problems in cystic fibrosis or Kartageners, and immunosuppression in inflammatory diseases such as sarcoidosis. When the supply of fibril precursor protein is substantially reduced by such methods, AA amyloid deposits frequently regress and renal function can improve. 51 If the acute phase response continues unabated, progressive amyloid deposition often results in end stage renal failure. In individuals who present with advanced renal disease even complete suppression of their inflammatory disease may not be sufficient to preserve their renal function and in all cases renal deterioration is accelerated by hypertension. Indeed hypertension can have serious consequences even years after renal function has stabilized following effective antiinflammatory therapy.
Systemic, AL amyloidosis
This is the commonest type of systemic amyloidosis accounting for more than 60% of cases. AL amyloidosis may potentially occur in association with any form of monoclonal B cell dyscrasia. 52, 53 AL fibrils are derived from monoclonal immunoglobulin light chains and generally consist of the whole or part of the variable (V L ) domain. [54] [55] [56] A number of conditions localized to the thoracic cavity can underlie systemic AL amyloidosis. Isolated plasmacytomas can secrete enough monoclonal free immunoglobulin light chains into the circulation to produce systemic AL amyloid deposits and may present as isolated chest masses (Figure 4 ). 57 Castleman's tumours, both unicentric and multicentric, can be associated with monoclonal immunoglobulin light chain production and are a rare cause of AL amyloidosis. The commonest condition managed by respiratory physicians which can cause both systemic and respiratory localized AL amyloid deposits is Sjogren's syndrome, which is discussed later.
Respiratory system symptoms arising from systemic AL amyloidosis
AL amyloid fibrils are derived from monoclonal immunoglobulin light chains. 56, 58, 59 A degree of amyloid deposition is seen in up to 15% of patients with myeloma, but the vast majority, more than 80%, of patients who present with clinically significant AL amyloidosis have very low grade and otherwise 'benign' monoclonal gammopathies. 60 AL amyloid usually presents in patients over the age of 50 years, although it can present in very young adults. 60 Clinical manifestations are extremely variable since almost any organ other than the brain can be directly involved. 61 Although certain clinical features are very strongly suggestive of AL amyloidosis (Table  3) , and multiple vital organ dysfunction is common, many patients present with non-specific symptoms such as malaise and weight loss. The outlook of untreated AL amyloid is far worse than AA type, with a five-year survival of approximately 10% and a 10year survival of less than 5%. 60 Most affected individuals eventually die of heart failure, uraemia or autonomic failure.
In most cases there is substantial histological cardiac involvement and restrictive cardiomyopathy is the presenting feature in up to one-third of patients and ultimately the cause of death in one half. 62 Renal involvement is frequent in AL amyloidosis and presents in the same manner as renal AA amyloid. 63 Gut involvement can cause motility disturbances (often secondary to autonomic neuropathy), malabsorption, perforation, haemorrhage or obstruction. 64 Peripheral neuropathy occurs in one fifth of cases and typically presents with a painful sensory polyneuropathy followed later by motor deficits. 60 Autonomic neuropathy causing orthostatic hypotension, impotence, and gastrointestinal disturbances may occur in isolation or with a peripheral neuropathy. 61 Although microscopic deposits of amyloid are universally present in the lungs, in the vast majority of cases dyspnoea is secondary to cardiac involvement. The chest radiograph is usually normal in systemic AL amyloidosis but may demonstrate a diffuse reticulonodular pattern. Lung function tests sometimes show a restrictive pattern and, rarely, reduced gas transfer due to extensive alveolar deposits. 65 Persistent pleural effusions have been described in 5.5% of patients ( Figure  5 ) and are commonly associated with amyloid heart disease. However they may also be due to amyloid induced disruption of normal pleural function and in this situation they are often refractory to management with diuretics and require recurrent drainage or pleurodesis. 66 The aim of treatment in AL amyloidosis is to suppress proliferation of the underlying B-cell clone and, therefore, production of the amyloid fibril precursor protein. There are, however, many difficulties. 67 Chemotherapy regimes are based on those used in multiple myeloma, but the plasma cell dyscrasias in most AL patients are relatively low grade and may be less chemosensitive. Diagnosis is difficult and can be delayed, and many patients have advanced multisystem disease which limits their options for chemotherapy. 67 Regression of amyloid is a gradual process which may not lead to measurable clinical improvement or recovery of organ function for many months, or even years, after successful suppression of the causative plasma cell dyscrasia. 68, 69 Mobilization of amyloid from the heart is much slower than from the liver or kidneys, and many patients with cardiac or multisystem dysfunction do not live long enough to benefit from chemotherapy, even when it has succeeded in suppressing their clonal disease. 70 However, despite these problems, many patients with AL amyloidosis do benefit substantially from chemotherapy. 70 Prolonged low intensity cytotoxic regimes such as oral melphalan and prednisolone are beneficial in about 20% of patients and this is the only treatment to have been proven in placebo controlled trials. 71 Although untested in comparative clinical trials, dose intensive infusional chemotherapy regimes such as vincristine, doxorubicin (Adriamycin) and dexamethasone ('VAD') 72, 73 and autologous peripheral blood stem-cell transplantation are almost certainly much more effective. [74] [75] [76] Very rigorous patient selection for high dose chemotherapy is essential because the procedure related mortality is extremely high in individuals with multiple organ involvement. 74, 77 Amyloidosis localized to the respiratory tract This was first described by Lesser in 1877 and a number of classifications have been suggested based upon radiographic or bronchoscopic findings. 78, 79 In general amyloidosis is best classified by the fibril protein (Table 1) , and then by the sites involved clinically. 80 Localized amyloid deposition is not uncommon, although often undiagnosed and results either from local production of fibril precursors, [81] [82] [83] or from properties inherent to the particular microenvironment, which favour fibril formation of a widely distributed precursor protein. 84 The vast majority of deposits are AL in type 85, 86 and symptomatic deposits occur most frequently in the eye, 87 skin, 88 respiratory 78, 89 or urogenital tracts. 90, 91 They are often associated with extremely subtle focal monoclonal B cell proliferation confined to the affected site and surgical resection of these localised 'amyloidomas' can sometimes be curative. 90 Symptomatic apparently localised amyloid deposits can rarely be manifestations of systemic disease and patients should always be fully investigated to exclude more generalized amyloid deposition. 28 Thorough evaluation of respiratory tract amyloidosis is required to determine the need for treatment and the most suitable modality. The paucity of controlled clinical trials means that management decisions have to be made on an individual basis. Broadly, speaking systemic chemotherapy is usually indicated for systemic AL amyloidosis and local intervention, according to symptoms for its localized forms.
Laryngeal amyloidosis
Amyloid represents 0.5-1% of benign laryngeal disease, its incidence increases with age but it occasionally affects young adults. 92 Discrete nodular and diffuse infiltrative types of laryngeal amyloid were described in 1919, 93 the diffuse pattern with an intact mucosa being more common, sometimes with tracheobronchial extension. 86 The amyloid deposits occur most commonly in the supraglottic larynx and usually present with hoarseness or rarely stridor, but can cause a sensation of 'fullness' in the throat, choking and dyspnoea on exertion. 94 The disorder is usually relatively benign but can be progressive or recur after treatment. Fatal haemorrhage has been reported. 95 Following complete histological diagnosis and evaluation of the disease extent, often by computed tomographic scan, endoscopic surgical 96, 97 or carbon-dioxide laser excision 98, 99 is the treatment of choice aiming to preserve voice quality and maintain airway patency. 100 As the underlying clonal plasma cell population is often diffuse and not excised patients may require repeated removal of the amyloid deposits. Local and systemic corticosteroids have no effect on laryngeal amyloidosis. 101 Very rarely apparently localized laryngeal amyloid deposits can be due a feature of hereditary systemic apolipoprotein AI amyloidosis. Four separate apolipoprotein variants have been reported to cause this 31, [102] [103] [104] and in three of these the major site of organ damage is the heart. Apolipoprotein AI is a major constituent of high density lipoprotein (HDL). 105 Wild type apolipoprotein AI is amyloidogenic and is present as traces of amyloid in human aortic atherosclerotic plaques in 10-20% of autopsies. 106 Numerous amyloidogenic variants have been reported and depending on the mutation, patients can present with massive abdominal visceral amyloid involvement, 107 predominant cardiomyopathy 104 or a familial amyloid polyneuropathy like syndrome. 108
Tracheobronchial amyloidosis
Tracheobronchial amyloidosis is an uncommon diagnosis although it may well be underreported. It is characterized by amyloid deposits primarily in the trachea and large bronchi, with extension at times into segmental bronchi and frequently involvement of the submucosal vessels. 78, 109 A literature review in 1983 identified only 67 cases worldwide, of which 57 were diffusely infiltrative (multifocal submucosal plaques) and the remainder were nodular or 'tumour-like'. 79 The disorder has been associated with tracheobronchopathia osteoplastica, which is characterized by calcified or cartilaginous submucosal nodules within the airways. [110] [111] [112] Tracheobronchial amyloidosis typically presents in the fifth and sixth decades although it can occur in younger age groups. 113, 114 Presenting symptoms include dyspnoea, persistent cough and haemoptysis. 113 Narrowing of airways can cause wheezing, distal atelectasis, recurrent pneumonia or lobar collapse ( Figure 6 ) and solitary nodules may be mistaken for endobronchial neoplasia. 115 The management of tracheobronchial amyloidosis is largely dependant upon symptoms; there is no proven drug therapy for tracheobronchial amyloidosis, although systemic chemotherapy has been tried in patients with progressive disease 113 with some anecdotal reports of success as has dimethylsulphoxide. Treatment options include bronchoscopic or surgical resection, as well as laser and external beam radiotherapy which can sometimes suppress the responsible clonal B cells within the tissue. 116 Management is largely dictated by the degree of symptoms and can involve intermittent bronchoscopic resection or stenting, 100 carbon dioxide laser ablation, Nd:YAG laser therapy 117, 118 and rarely radiotherapy, 119 extensive airway involvement may require open resection. 120 Although symptomatic tracheobronchial amyloidosis is usually localized, its course is not always benign and overall survival is only 31% to 43% at four to six years: three of seven cases followed up by Hui died of respiratory failure or secondary pneumonia, 121 and three of four Mayo Clinic patients died within 79 months of diagnosis. 78 Of the 10 patients followed up by the Boston group, three died of respiratory complications, an average of nine years after diagnosis, six patients underwent multiple laser resections and four required tracheostomies. 113 In contrast, three of four patients followed up by Cordier for a median of eight years remained well. 109
Parenchymal pulmonary amyloidosis
Amyloid within the lung parenchymal tissue is the most frequently detected respiratory manifestation of amyloidosis. 122 It can be divided radiographically into solitary/multiple nodules or a diffuse alveolar-septal pattern. 123, 124 Nodular pulmonary amyloidosis is almost always localized and is usually an incidental finding on chest radiography. Although the lesions may be dramatic and need to be differentiated from neoplasia the prognosis is usually excellent. Amyloid nodules in the lung parenchyma are usually peripheral and subpleural, occurring preferentially the lower lobes, may be bilateral and range in diameter from 0.4-15 cm. They grow slowly and may cavitate or calcify. 122, 124, 125 Larger nodules can occasionally produce space occupying effects but otherwise no treatment is required.
Sjogren's disease is a chronic organ-specific autoimmune disease characterized by lymphocytic infiltration into the salivary and lacrimal glands which predominantly affects women. 126 It is associated with a 44-fold increase in lymphoproliferative disorders and can be divided into three stages according to the extent of organ damage and disease progression: stage 1, accounting for 45%, is sicca syndrome alone; stage 2, accounting for 50%, includes lymphocytic damage to the pulmonary, renal, hepatic, haematological and/or skin tissues. Approximately 5% of patients develop stage 3 disease with malignant lymphomas. This evolution from polyclonal lymphoproliferation to clonal disease to mucosa-associated lymphoid tissue (MALT) lymphoma, and finally to high-grade malignant lymphoma is associated with an increasing risk of AL amyloidosis as monoclonal breakthrough occurs. AL amyloidosis is a well recognized complication of Sjogren's, it is most often associated with localised nodular pulmonary amyloidosis 127 but can also affect the breast tissues 128 and may result in systemic disease. 129 Diffuse amyloid deposition within the lung parenchyma is usually associated with systemic AL amyloidosis and involvement of other organ systems; 109 post mortem series have confirmed that diffuse parenchymal amyloid is common in systemic AL amyloidosis. 130, 131 As discussed above signs are often scanty and clinical sequelae are rare and the most appropriate treatment is chemotherapy aimed at the underlying plasma cell clone.
Mediastinal and hilar amyloid lymphadenopathy
Infiltration of lymphoid tissue by amyloid deposits resulting in massive lymphadenopathy is not uncommon. Although hilar and mediastinal lymphadenopathy can be associated with localized pulmonary amyloidosis particularly in patients with Sjogren's syndrome and secondary lymphoma its discovery should prompt a search for an underlying B cell dyscrasia. 79, 132 The majority of patients with amyloid lymphadenopathy have detectable circulating monoclonal immunoglobulin typically associated with very low grade lymphoplasmacytic lymphoma or Waldenstrom's macroglobulinaemia. 133 Disease progression may be exceptionally slow and node calcification is well recognised. 123, 134 Amyloid adenopathy has occasionally been reported to cause tracheal compression and superior vena caval obstruction. Treatment centres on treating the underlying lymphoproliferative disease but surgical resection may become necessary.
Conclusion
Amyloidosis can both complicate long standing respiratory conditions and be deposited within the respiratory system itself. The manifestations, significance and prognosis of amyloid deposits depend on their aetiology and anatomical distribution and can be benign or life threatening. Each patient requires thorough evaluation to determine their optimal treatment. In most cases of localised disease management is essentially supportive or involves resection of symptomatic deposits. In contrast, systemic anti-inflammatory treatment and chemotherapy can be extremely effective in patients with the systemic AA and AL forms of the disease. Encouragingly, the development of specific drug therapies to stabilize amyloid precursor proteins, interfere with amyloid fibrillogenesis and accelerate the clearance of tissue amyloid deposits are all on the horizon. 135 
